ClinicalTrials.gg
Status unknownNCT03349008MAGIC-101Updated Nov 21, 2017

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

A Phase 4 interventional study of Entecavir and Magnesium Isoglycyrrhizinate in Chronic Hepatitis b and Liver Inflammation, sponsored by Cttq. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-11-21.

Sponsored by Cttq (part of Sino Biopharmaceutical Limited) · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Planned enrollment
3rd of 13
480 · median 116
Started
2017
the only one that year
Phase 4
2 of 13
none open now
Registered
3rd of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 3rd largest by planned enrollment, is the only one that started in 2017, is one of 2 in phase 4, and was the 3rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.

Read the detailed description

Chronic hepatitis B(HBV) has a high prevalence (>8%) in China. Entecavir, aguanosine analog, is a potent and selective inhibitor of HBV DNA polymerase.

Glycyrrhizin has been used for more than 30 years in the treatment of liver diseases in Asian countries, who can relieve necro-inflammatory and liver fibrosis or cirrhosis Recent study has shown that inflammation plays the important role in chronic HBV and fibrosis or cirrhosis disease progression, but antiviral therapy only may not reduce inflammation ideally. The addition of glycyrrhizin to entecavir in the treatment may slow disease progression in patients with chronic HBV and advanced fibrosis or cirrhosis.

03

Conditions studied

  • Chronic Hepatitis b
  • Liver Inflammation

Keywords

  • necro-inflammatory
  • glycyrrhizin
  • entecavir
  • hepatic biological parameters
  • liver fibrosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • surface antigen [HBsAg]-positive,
  • Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody (HBeAb)-positive disease were eligible,
  • Serum (ALT) levels 3-10×the (ULN),serum total (TBIL)levels\<2×ULN

Exclusion criteria

Exclusion Criteria:

  • Co-infection with virus, hepatitis D virus, or ;
  • Other forms of liver disease;
  • More than 24 weeks of therapy with a nucleoside or nucleotide analog with activity against , and therapy with any anti-HBV drug within 24 weeks prior to randomization;
  • More than 12 weeks of therapy with liver protectants, and therapy with glycyrrhizin;
  • Has decompensated liver function or has a hint of hepatocellular carcinoma (HCC);
  • During the study patients were not allowed to use other medicines.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo

    Drug: Entecavir · Drug: Magnesium Isoglycyrrhizinate Placebo · Drug: Diammonium Glycyrrhizinate Placebo

  • Experimental
    Experimental group

    Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate

    Drug: Entecavir · Drug: Magnesium Isoglycyrrhizinate · Drug: Diammonium Glycyrrhizinate

Interventions

  • Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based

    Also known as: Entecavir Pill

  • Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based

    Also known as: Magnesium Isoglycyrrhizinate Injection

  • Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based

    Also known as: Diammonium Glycyrrhizinate Enteric-coated Capsules

  • DrugMagnesium Isoglycyrrhizinate Placebo

    Magnesium Isoglycyrrhizinate Injection Placebo

    Also known as: Magnesium Isoglycyrrhizinate Injection Placebo

  • DrugDiammonium Glycyrrhizinate Placebo

    Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo

    Also known as: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo

06

What researchers measure

Primary outcomes

  1. Change of ALT(Alanine aminotransferase)

    The ALT levels of plasma are measured at baseline and at 24 weeks. The normal value was 0-40 U/L.

    Time frame: baseline and 24 weeks

Secondary outcomes

  1. Change of Liver inflammatory

    Liver inflammatory of the liver biopsies is performed at baseline and 24 weeks evaluated by Knodell HAI score.

    Time frame: baseline and 24 weeks

  2. Change of Liver Fibrosis

    Liver Fibrosis is performed at baseline and 96 weeks evaluated by Fibroscan examination.

    Time frame: baseline and 96 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2017; primary completion for Dec 2019, 25 months later.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2017
First posted
Nov 21, 2017
StartEst.
Nov 25, 2017
Primary completionEst.
Dec 31, 2019
CompletionEst.
May 31, 2020
Last update
Nov 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03349008
Lead sponsor
Cttq
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
Nov 25, 2017 (estimated)
Primary completion
Dec 31, 2019 (estimated)
Completion
May 31, 2020 (estimated)
Last update
Nov 21, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Magnesium isoglycyrrhizinate · Glycyrrhizic Acid

Start the discussion